Advertisement
YOU ARE HERE: LAT HomeCollectionsIcn Biomedicals
IN THE NEWS

Icn Biomedicals

BUSINESS
April 2, 1993 | MICHAEL FLAGG, TIMES STAFF WRITER
Drug and health-care concern ICN Pharmaceuticals Inc. said Thursday that it lost $65 million, or $4.67 a share, last year. That contrasted with a profit of $5.9 million, or 40 cents a share, for 1991. Annual sales rose to $551.8 million from $460.4 million. ICN blamed the loss on a publicly traded subsidiary, ICN Biomedicals Inc., which had to take a $73-million accounting charge against earnings in the fourth quarter.
Advertisement
BUSINESS
April 26, 1990 | GREGORY CROUCH, TIMES STAFF WRITER
The Securities and Exchange Commission is investigating trading in the stock of ICN Biomedicals during 1988, the company confirmed Wednesday. The Costa Mesa-based chemical research company said it received a request from the SEC in January asking that it voluntarily provide information about trading in the company's stock. The inquiry also involves the trading of stock by an undisclosed company or individual in companies considering a merger or acquisition of ICN Biomedicals.
BUSINESS
May 16, 1990
ICN Biomedicals, a Costa Mesa supplier of biotechnology research and medical diagnostic products, said Tuesday that its price for acquiring Flow Laboratories has been reduced from $41.5 million to $37.6 million. Flow Laboratories is a supplier of life sciences research products that was acquired by ICN in November, 1989. The adjustment in the purchase price was based on a financial review of Flow Laboratories by an independent auditing firm, said Jack Sholl, an ICN spokesman.
Los Angeles Times Articles
|